


IVECS Limited : Light-Activated Hydrogel

Principal Investigator: Professor Joseph Y.K. Chan

daniel.ng@abic.hk
+852-68786955

Technology



Key Advantages

Compared to **current treatment options:**

DED: IPL-based therapies, ointments, eye drops

BK: Antibiotic eye drops, topical corticosteroids

FK: Antifungal medication, surgical treatments

Our patch for DED

- Addresses Root Cause
- Provides Long-term relief
- Easy-to-use
- Safe and Non-invasive
- Comfortable
- Affordable

Our lens for BK

Disease progression can be halted before knowing the type of infection, acting as a first-line treatment

- Broad-spectrum antibacterial ability
- Does not cause antibiotic resistance
- Non-cytotoxic
- High efficacy

Our lens for FK

- Broad-spectrum antifungal ability
- Non-cytotoxic
- High efficacy

Stage of Development

DED: Animal trials, regulatory approval, mass manufacturing, marketing
*Estimated time-to-market: 1 year

BK: Product optimization, clinical trials, mass manufacturing

FK: Research & development, product optimization, clinical trials, mass manufacturing

Opportunities

2025 DED Market Valuation: 11.7 billion USD (CAGR of 8.5%)

Business Model: B2C & B2B2C, retail as a wellness consumer product using a razor/razorblade business model for recurring revenue

2025 Keratitis (BK & FK) Market Valuation: 887.5 million USD (CAGR 6.2%)

Business Model: B2B, sell as viable treatment option to clinicians, hospitals, medical centres, integrated delivery networks (HA, Gleneagles, Kaiser Permanente, etc)

Intellectual Property

DED: US63/790,848 (US provisional patent filed on 18 April 2025); HKU Internal ref no. IPO1639

BK Contact Lens: US20240366735A1 (US non-provisional patent – pending); HKU Internal ref no. IPO1228